FDA Clearance Tracker · DEN210056
Procise IFX
Last checked: Nov 20, 2026Latest source record: Sep 29, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Sep 29, 2023
De Novo granted
Time to decision
660 days
Received Dec 8, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN210056
- Device name
- Procise IFX
- Applicant
- Procisedx, Inc.
- Applicant location
- San Diego, CA
- Received
- Dec 8, 2021
- Decided
- Sep 29, 2023
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device type
- Infliximab Test System (QXT)
- Device class
- Class II
- Regulation
- 21 CFR 862.3115
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN210056
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Procisedx, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Procise ADLNew device typeDe Novo
DEN220023 · Decided Sep 29, 2023 · 543 days after receipt
Device type: Adalimumab Assay (QYD) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.